Business review P06P53 Governance and remuneration P54P90 Financial statements P91P182 Shareholder information P183P204 113 Notes to the financial statements 10 Employee costs 2009 2008 2007 m m m Wages and salaries 5,387 4,640 4,444 Social security costs 661 653 527 Pension and other post-employment costs, including augmentations Note 28 491 505 313 Cost of share-based incentive plans 179 241 237 Severance and other costs from integration and restructuring activities 449 485 212 7,167 6,524 5,733 In 2009, wages and salaries increased by 4% in CER terms.
The Group provides benefits to employees, commensurate with local practice in individual countries, including, in some markets, healthcare insurance, subsidised car schemes and personal life assurance.
2009 2008 2007 The average number of persons employed by the Group including Directors during the year: Number Number Number Manufacturing 31,467 33,372 33,975 Selling, general and administration 53,183 52,115 53,707 Research and development 14,204 15,646 15,719 98,854 101,133 103,401 The average number of Group employees excludes temporary and contract staff.
The numbers of Group employees at the end of each financial year are given in the Financial record on page 194.
The average number of persons employed by GlaxoSmithKline plc in 2009 was nil 2008 nil.
The compensation of the Directors and Senior Management members of the CET in aggregate, was as follows: 2009 2008 2007 m m m Wages and salaries 23 17 16 Social security costs 1 1 1 Pension and other post-employment costs 3 3 3 Cost of share-based incentive plans 4 12 15 31 33 35 11 Finance income 2009 2008 2007 m m m Interest income arising from: cash and cash equivalents 46 107 98 available-for-sale investments 15 31 49 derivatives at fair value through profit or loss 5 159 79 loans and receivables 11 22 27 Realised gains on liquid investments 2 1 Fair value adjustments on derivatives at fair value through profit or loss 3 4 Net investment hedge ineffectiveness 4 13 7 Unwinding of discounts on assets 2 1 1 70 313 262 All derivatives at fair value through profit or loss other than designated and effective hedging instruments see Note 41, Financial instruments and related disclosures are classified as held-for-trading financial instruments under IAS 39.
Interest income arising from derivatives at fair value through profit or loss relates to swap interest income.
